CN112424175B - 一种lsd1抑制剂的盐及其晶型 - Google Patents

一种lsd1抑制剂的盐及其晶型 Download PDF

Info

Publication number
CN112424175B
CN112424175B CN201980047189.0A CN201980047189A CN112424175B CN 112424175 B CN112424175 B CN 112424175B CN 201980047189 A CN201980047189 A CN 201980047189A CN 112424175 B CN112424175 B CN 112424175B
Authority
CN
China
Prior art keywords
crystal form
compound iii
compound
lsd1
whose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980047189.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN112424175A (zh
Inventor
赵乐乐
孙建军
吴凌云
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CN112424175A publication Critical patent/CN112424175A/zh
Application granted granted Critical
Publication of CN112424175B publication Critical patent/CN112424175B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980047189.0A 2018-07-20 2019-07-19 一种lsd1抑制剂的盐及其晶型 Active CN112424175B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810804068 2018-07-20
CN2018108040683 2018-07-20
PCT/CN2019/096842 WO2020015745A1 (zh) 2018-07-20 2019-07-19 一种lsd1抑制剂的盐及其晶型

Publications (2)

Publication Number Publication Date
CN112424175A CN112424175A (zh) 2021-02-26
CN112424175B true CN112424175B (zh) 2022-10-28

Family

ID=69163657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980047189.0A Active CN112424175B (zh) 2018-07-20 2019-07-19 一种lsd1抑制剂的盐及其晶型

Country Status (8)

Country Link
US (1) US12024494B2 (enExample)
EP (1) EP3825309B1 (enExample)
JP (1) JP7358466B2 (enExample)
KR (1) KR102778948B1 (enExample)
CN (1) CN112424175B (enExample)
AU (1) AU2019303777B2 (enExample)
CA (1) CA3106484C (enExample)
WO (1) WO2020015745A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021228146A1 (zh) * 2020-05-12 2021-11-18 石药集团中奇制药技术（石家庄）有限公司 一种lsd1抑制剂的用途
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
AU2023385514A1 (en) 2022-11-24 2025-07-10 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN116069221A (zh) * 2022-12-27 2023-05-05 北京字跳网络技术有限公司 媒体内容的展示方法、装置、电子设备和存储介质
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705675A1 (fr) * 1993-05-27 1994-12-02 Smithkline Beecham Labo Pharma Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
CN102947265A (zh) * 2010-04-19 2013-02-27 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
CN103124724A (zh) * 2010-07-29 2013-05-29 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
CN103857393A (zh) * 2011-03-25 2014-06-11 葛兰素史密斯克莱知识产权（第2号）有限公司 环丙基胺作为lsd1抑制剂
WO2017195216A1 (en) * 2016-05-09 2017-11-16 Jubilant Biosys Limited Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
WO2018137644A1 (zh) * 2017-01-24 2018-08-02 南京明德新药研发股份有限公司 Lsd1抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084160A1 (en) * 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
KR102710120B1 (ko) * 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
PE20190377A1 (es) * 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705675A1 (fr) * 1993-05-27 1994-12-02 Smithkline Beecham Labo Pharma Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
CN102947265A (zh) * 2010-04-19 2013-02-27 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
CN103124724A (zh) * 2010-07-29 2013-05-29 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
CN103857393A (zh) * 2011-03-25 2014-06-11 葛兰素史密斯克莱知识产权（第2号）有限公司 环丙基胺作为lsd1抑制剂
WO2017195216A1 (en) * 2016-05-09 2017-11-16 Jubilant Biosys Limited Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
WO2018137644A1 (zh) * 2017-01-24 2018-08-02 南京明德新药研发股份有限公司 Lsd1抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
EP3825309A4 (en) 2022-03-23
US20210317096A1 (en) 2021-10-14
CN112424175A (zh) 2021-02-26
CA3106484A1 (en) 2020-01-23
KR102778948B1 (ko) 2025-03-07
AU2019303777A1 (en) 2021-02-11
JP7358466B2 (ja) 2023-10-10
AU2019303777B2 (en) 2023-01-19
JP2021530565A (ja) 2021-11-11
CA3106484C (en) 2024-06-25
US12024494B2 (en) 2024-07-02
KR20210034058A (ko) 2021-03-29
EP3825309A1 (en) 2021-05-26
EP3825309B1 (en) 2023-09-06
WO2020015745A1 (zh) 2020-01-23

Similar Documents

Publication Publication Date Title
CN112424175B (zh) 一种lsd1抑制剂的盐及其晶型
EP3502103A1 (en) Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor
WO2020221358A1 (zh) Wee1抑制剂化合物的晶型及其应用
CN115485282B (zh) 一种氧氮杂螺环化合物、其盐型及其晶型
AU2021348707A1 (en) Crystal form of pyridinylphenyl compound and preparation method therefor
EP4046686A1 (en) Salt types, crystal forms, and preparation methods for benzopyrazole compounds as rho kinase inhibitors
RU2536685C2 (ru) Фармацевтически приемлемые соли тимодепрессина и способ их получения
WO2020228729A1 (zh) 喹唑啉酮类化合物的晶型及其制备方法
CN110167554B (zh) 一种具有抗癌作用的化合物及其制备方法和应用
RU2794977C2 (ru) Соль ингибитора lsd1 и её полиморфная форма
CN117843638A (zh) 基于rsl3诱导gpx4蛋白降解的双功能分子化合物的制备与应用
HK40038512A (en) Salt of lsd1 inhibitor and a polymorph thereof
HK40038512B (en) Salt of lsd1 inhibitor and a polymorph thereof
CN112585120B (zh) 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法
EP4089086B1 (en) Crystal form of pyrrolidinyl urea derivative and application thereof
CN115109083B (zh) Pyridostatin类化合物及其制备方法、应用、药物组合物
US12391653B2 (en) Salt form and crystal form of mutant IDH1 inhibitor and preparation method therefor
EP3677581A1 (en) Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof
CN114096541B (zh) 一种p53-MDM2抑制剂的晶型及其制备方法
WO2022237682A1 (zh) 吡咯并三嗪类化合物的盐型、其晶型及其制备方法
CN119264137A (zh) 一种化合物a的晶型a及其制备方法与应用
WO2021164789A1 (zh) 一种吡唑并嘧啶类化合物的晶型及其应用
WO2024037532A1 (zh) 一种噻吩并嘧啶酮衍生物的盐型及晶型
CN115947677A (zh) 一种药物前体化合物及其制备方法和应用
WO2021185312A1 (zh) 一种tlr8激动剂晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40038512

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant